FDA Inspection 1202251 — Dipharma Francis Srl
The FDA completed an inspection of Dipharma Francis Srl on February 25, 2022 in Mereto Di Tomba. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- February 25, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Mereto Di Tomba (Italy)
Additional Details
Mutual Recognition Agreement (MRA)